Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.

<style> .row-link-block { color: #000; padding-bottom: 4rem; display: block; } .row-link-block h3 { margin-top:0; } .biography-block h2, h3 { margin-top: 0; } .biography-block img { margin:0 2rem 1rem 0; } .pp-card { margin-bottom: 2rem; } .pp-card .row-link-block h3 { margin:1.5rem 1rem 1rem 1rem; } .pp-card p, .pp-card img { margin: 1rem; } .pp-card img { width: 90%; } .pp-card p { color: #555; font-size:.9em; } .pp-card .row-link-block:hover { text-decoration: none; } .pp-card .row-link-block:hover p { color: #000; } </style>

Key facts

Time frame: 2019 to 2021

Origin: Spontaneous Application

Project Website EpiSensor



EpiSensor is the epilepsy component of RADAR-CNS a platform and infrastructure for real-time data streaming from wearable devices and smartphone apps, to allow data related to clinical events to be associated with contextual information.


Project Description

RADAR-CNS is a major new research programme funded by IMI2 (grant agreement no 115902), co-led by King’s College London and Janssen Pharmaceutica NV, which is developing new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology. RADAR-CNS aims to improve patients’ quality of life, and potentially to change how these and other chronic disorders are treated. In particular, wearable devices are expected to provide more objective and precise measurements of seizure frequency as opposed to self-reported seizure occurrence, hence improving clinical management. Timely seizure detection might also enable more rapid intervention to prevent seizure-related risks including death.

EpiSensor, the epilepsy component of RADAR-CNS has considerable experience with various wearable sensor devices and has collected data using wearables in a substantial set of subjects experiencing seizures during Epilepsy Monitoring Unit evaluation.  There are numerous wearable sensors on the market, some of which are approved (CE marked or FDA approved) for seizure detection; many of these devices are connectable to the internet. At the current time, the reliability, usability and acceptability of these devices as seizure detectors is insufficiently clear.

RADAR-CNS has created a platform and infrastructure for real-time data streaming from wearable devices and smartphone apps, to allow data related to clinical events (eg. seizures) to be associated with contextual information (eg. sleep/wake, activity, mood, cognition etc.).

HBP has a growing interest in epilepsy and related IOT opportunities. HBP aims to iteratively refine and reuse of models and analyses that will lead to identification of Biological Signatures of Diseases and novel classifications of brain disorders, thus more accurate diagnoses and personalized medicine – a goal highly aligned with RADAR-CNS in this setting.



EpiSensor opens the opportunity to combine datasets and data analyses in a federated manner in particular to the field of epilepsy.


Collaboration with HBP 

KCL RADAR-CNS data collected in patients with epilepsy from wearables and from intracerebral EEG data in SP8 will be use jointly to enhance HBP capacities to deliver relevant biological signatures of epilepsy.